Fasinumab Explained

Fasinumab is a human monoclonal antibody designed for the treatment of acute sciatic pain.[1] [2]

This drug was developed in collaboration by Teva Pharmaceutical Industries and Regeneron Pharmaceuticals.

It is currently at Phase III trials (NCT03245008, NCT02683239, and NCT03161093).[3]

See also

Notes and References

  1. Web site: Fasinumab . Statement On A Nonproprietary Name Adopted By The USAN Council . .
  2. Tiseo PJ, Ren H, Mellis S . Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study . Journal of Pain Research . 7 . 523–530 . 2014 . 25210473 . 4155988 . 10.2147/JPR.S65974 . free .
  3. Oo WM, Hunter DJ . Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review . BioDrugs . 35 . 6 . 611–641 . November 2021 . 34807432 . 10.1007/s40259-021-00504-8 . 244509341 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Fasinumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.